文献速递精神分裂症与精神病性障碍

TV-46000长效皮下注射利培酮治疗精神分裂症的疗效与安全性

Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria.
PubMed 文献 · Lancet Psychiatry · 2023-11-02

RISE研究为3期随机双盲安慰剂对照试验,纳入544例精神分裂症患者,评估TV-46000皮下注射(每月一次或每两月一次)预防复发的疗效。

要点

  • 常见治疗相关不良事件为注射部位结节、体重增加和锥体外系症状,安全性与其他利培酮剂型一致。

核心结论

  • 在精神分裂症患者中,皮下注射TV-46000每月一次和每两月一次均显著延迟了即将复发的时间,且具有有利的风险获益特征。

研究设计与样本

  • RISE研究为3期随机双盲安慰剂对照试验,在美国和保加利亚的69个临床中心进行。
  • 研究分两阶段:12周开放标签口服利培酮稳定期,随后为开放终点、随机双盲、安慰剂对照的复发预防期。
  • 筛查1267例,入组863例,544例随机分配至TV-46000每月一次(n=183)、每两月一次(n=180)或安慰剂(n=181)。
  • 纳入标准为DSM-5诊断精神分裂症超过1年且筛查前24个月内有至少一次复发。

主要发现

  • 常见治疗相关不良事件(≥5%且TV-46000组高于安慰剂)包括注射部位结节(每月一次7%、每两月一次7%、安慰剂3%)、体重增加(4%、6%、2%)和锥体外系症状(5%、3%、0%)。
  • 严重不良事件发生率:每月一次组4%、每两月一次组6%、安慰剂组8%。

关键数值与推荐

  • 主要终点为意向治疗人群至即将复发的时间,预设停止标准为至少90例复发事件。

临床怎么用

  • TV-46000可作为成人精神分裂症患者的长效皮下注射抗精神病药治疗选择。
  • 每月一次或每两月一次的给药方案可能有助于提高依从性并预防复发。

局限性

  • 研究未报告对口服利培酮稳定期患者的长期随访数据。
  • 研究未报告对TV-46000与其他长效抗精神病药的头对头比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: TV-46000 is a long-acting, subcutaneous, antipsychotic agent that combines risperidone and an innovative, copolymer-based drug delivery technology in a suspension that was approved in April, 2023 for subcutaneous use. The aim of the phase 3 Risperidone Subcutaneous Extended-release (RISE) study was to evaluate the efficacy of TV‑46000 in schizophrenia. METHODS: The RISE study consisted of two treatment stages: a 12-week, open-label stabilisation phase with oral risperidone (stage 1), and an open-ended, randomised, double-blind, placebo-controlled, relapse-prevention phase with subcutaneous TV-46000 (stage 2) done at 69 clinical sites across the USA and Bulgaria. Patients diagnosed with schizophrenia more than 1 year before screening by DSM-5 criteria and confirmed at screening by the Structured Clinical Interview for DSM-5 and who had at least one relapse within 24 months before screening were eligible for enrolment. Patients who were outpatients and stabilised in stage 1 continued to stage 2 and were randomly assigned 1:1:1 by a computer-generated randomisation list to receive either subcutaneous TV-46000 once monthly, TV-46000 once every 2 months, or placebo until relapse, early discontinuation, or the study was stopped because the prespecified stopping criterion of at least 90 relapse events was met. The primary endpoint was time to impending relapse of the intention-to-treat patient population in stage 2. This study is registered with ClinicalTrials.gov, number NCT03503318, and is complete. FINDINGS: The study enrolled the first patient on June 1, 2018, and the last patient completed on Dec 3, 2020. 1267 patients were screened, 863 enrolled, and 544 (male, n=332 [61%], female, n=212 [39%]; mean [SD] age, 49·3 [10·98] years; Black or African American, n=322 [59%]; White, n=206 [38%]; Asian, n=7 [1%]; Native Hawaiian or other Pacific Islander, n=2 [<1%]; race not reported, n=3 [<1%]; other race, n=4 [<1%]; Hispanic or Latinx, n=117 [22%]) randomly assigned to subcutaneous TV-46000 once monthly (n=183), TV-46000 once every 2 months (n=180), or placebo (n=181). Time to impending relapse was significantly prolonged by 5·0 times with TV-46000 once monthly (hazard ratio, 0·200 [95% CI 0·109-0·367]; p<0·0001) and by 2·7 times with TV-46000 once every 2 months (0·375 [0·227-0·618]; p<0·0001) versus placebo. Most frequently reported treatment-related adverse events (ie, ≥5% of patients in either TV-46000 group) that occurred more often in patients receiving TV-46000 (once monthly or once every 2 months) versus placebo were injection site nodules (7% for TV-46000 once monthly, 7% for TV-46000 once every 2 months, 3% for placebo), weight increased (4%, 6%, 2%, respectively), and extrapyramidal disorder (5%, 3%, 0% respectively). Serious adverse events were reported for eight (4%) patients in the TV-46000 once-monthly group, ten (6%) patients in the TV-46000 once-every-2-months group, and 14 (8%) patients in the placebo group. The safety profile of TV-46000 was consistent with other approved formulations of risperidone. No new safety signals were identified. INTERPRETATION: In patients with schizophrenia, subcutaneous TV-46000 once monthly and once every 2 months significantly delayed impending relapse versus placebo. TV-46000 is an effective long-acting, subcutaneous, antipsychotic agent treatment option in adult patients with schizophrenia, with a favourable benefit-risk profile. FUNDING: Teva Branded Pharmaceutical Products R&D.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Kane JM, Harary E, Eshet R, et al. Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria. Lancet Psychiatry. 2023. PMID: 37924833. doi:10.1016/S2215-0366(23)00288-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。